Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and ...

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

Detailed price information for Unitedhealth Group Inc (UNH-N) from The Globe and Mail including charting and trades.

Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

More than 20 million people globally are injecting themselves with GLP-1s... Weight-loss pills will only see that explode ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023, led to a surge in demand for compounded versions of the drugs.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...